|
1
|
Maris JM: Recent advances in
neuroblastoma. N Engl J Med. 362:2202–2211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Howlader N, Noone A, Krapcho M, et al:
SEER Cancer Statistics Review, 1975–2011. National Cancer
Institute; Bethesda, MD: 2012, http://seer.cancer.gov/csr/1975_2011/.
Accessed August 14, 2014
|
|
3
|
London WB, Castleberry RP, Matthay KK, et
al: Evidence for an age cutoff greater than 365 days for
neuroblastoma risk group stratification in the Children’s Oncology
Group. J Clin Oncol. 23:6459–6465. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lebanese Ministry of Public Health and
Epidemiology Surveillance Program. National cancer registry. 2007,
http://www.moph.gov.lb/Prevention/Surveillance/Pages/Cancer.aspx.2010.
Accessed December 9, 2013
|
|
5
|
Ries L, Smith M, Gurney J, Linet M, Tamra
T, Young J and Bunin G: Cancer incidence and survival among
children and adolescents: United States SEER Program 1975–1995. NIH
publication no. 99-4649. National Cancer Institute; Bethesda, MD:
1999
|
|
6
|
Maris JM, Hogarty MD, Bagatell R and Cohn
SL: Neuroblastoma. Lancet. 369:2106–2120. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brodeur GM: Neuroblastoma: biological
insights into a clinical enigma. Nat Rev Cancer. 3:203–216. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kushner BH, Gilbert F and Helson L:
Familial neuroblastoma. Case reports, literature review, and
etiologic considerations. Cancer. 57:1887–1893. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brodeur GM, Seeger RC, Schwab M, Varmus HE
and Bishop JM: Amplification of N-myc in untreated human
neuroblastomas correlates with advanced disease stage. Science.
224:1121–1124. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Seeger RC, Brodeur GM, Sather H, Dalton A,
Siegel SE, Wong KY and Hammond D: Association of multiple copies of
the N-myc oncogene with rapid progression of neuroblastomas. N Engl
J Med. 313:1111–1116. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tonini GP and Romani M: Genetic and
epigenetic alterations in neuroblastoma. Cancer Lett. 197:69–73.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kushner BH, LaQuaglia MP, Bonilla MA, et
al: Highly effective induction therapy for stage 4 neuroblastoma in
children over 1 year of age. J Clin Oncol. 12:2607–2613.
1994.PubMed/NCBI
|
|
13
|
Simon T, Längler A, Berthold F, Klingebiel
T and Hero B: Topotecan and etoposide in the treatment of relapsed
high-risk neuroblastoma: results of a phase 2 trial. J Pediatr
Hematol Oncol. 29:101–106. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Daly AK: Pharmacogenetics of the major
polymorphic metabolizing enzymes. Fundam Clin Pharmacol. 17:27–41.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ashton LJ, Murray JE, Haber M, Marshall
GM, Ashley DM and Norris MD: Polymorphisms in genes encoding drug
metabolizing enzymes and their influence on the outcome of children
with neuroblastoma. Pharmacogenet Genomics. 17:709–717. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang Z, Roy P and Waxman DJ: Role of
human liver microsomal CYP3A4 and CYP2B6 in catalyzing
N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem
Pharmacol. 59:961–972. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Petros WP, Hopkins PJ, Spruill S, et al:
Associations between drug metabolism genotype, chemotherapy
pharmacokinetics, and overall survival in patients with breast
cancer. J Clin Oncol. 23:6117–6125. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Walker D, Flinois JP, Monkman SC, et al:
Identification of the major human hepatic cytochrome P450 involved
in activation and N-dechloroethylation of ifosfamide. Biochem
Pharmacol. 47:1157–1163. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dennison JB, Jones DR, Renbarger JL and
Hall SD: Effect of CYP3A5 expression on vincristine metabolism with
human liver microsomes. J Pharmacol Exp Ther. 321:553–563. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Relling MV, McLeod HL, Bowman LC and
Santana VM: Etoposide pharmacokinetics and pharmacodynamics after
acute and chronic exposure to cisplatin. Clin Pharmacol Ther.
56:503–511. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
McCune JS, Risler LJ, Phillips BR, Thummel
KE, Blough D and Shen DD: Contribution of CYP3A5 to hepatic and
renal ifosfamide N-dechloroethylation. Drug Metab Dispos.
33:1074–1081. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bosch TM, Meijerman I, Beijnen JH and
Schellens JH: Genetic polymorphisms of drug-metabolising enzymes
and drug transporters in the chemotherapeutic treatment of cancer.
Clin Pharmacokinet. 45:253–285. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
van Schaik RH, de Wildt SN, van Iperen NM,
Uitterlinden AG, van den Anker JN and Lindemans J: CYP3A4-V
polymorphism detection by PCR-restriction fragment length
polymorphism analysis and its allelic frequency among 199 Dutch
Caucasians. Clin Chem. 46:1834–1836. 2000.PubMed/NCBI
|
|
24
|
van Schaik RH, van der Heiden IP, van den
Anker JN and Lindemans J: CYP3A5 variant allele frequencies in
Dutch Caucasians. Clin Chem. 48:1668–1671. 2002.PubMed/NCBI
|
|
25
|
Raggi CC, Bagnoni ML, Tonini GP, et al:
Real-time quantitative PCR for the measurement of MYCN
amplification in human neuroblastoma with the TaqMan detection
system. Clin Chem. 45:1918–1924. 1999.PubMed/NCBI
|
|
26
|
Peirson SN, Butler JN and Foster RG:
Experimental validation of novel and conventional approaches to
quantitative real-time PCR data analysis. Nucleic Acids Res.
31:e732003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lamba JK, Lin YS, Schuetz EG and Thummel
KE: Genetic contribution to variable human CYP3A-mediated
metabolism. Adv Drug Deliv Rev. 54:1271–1294. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Busi F and Cresteil T:
Phenotyping-genotyping of alternatively spliced genes in one step:
study of CYP3A5*3 polymorphism. Pharmacogenet Genomics.
15:433–439. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sinues B, Vicente J, Fanlo A, et al:
CYP3A5*3 and CYP3A4*1B allele distribution
and genotype combinations: differences between Spaniards and
Central Americans. Ther Drug Monit. 29:412–416. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Amirimani B, Ning B, Deitz AC, Weber BL,
Kadlubar FF and Rebbeck TR: Increased transcriptional activity of
the CYP3A4*1B promoter variant. Environ Mol Mutagen.
42:299–305. 2003. View Article : Google Scholar
|
|
31
|
Lim HJ, Gill S, Speers C, et al: Impact of
irinotecan and oxaliplatin on overall survival in patients with
metastatic colorectal cancer: a population-based study. J Oncol
Pract. 5:153–158. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gellner K, Eiselt R, Hustert E, et al:
Genomic organization of the human CYP3A locus: identification of a
new, inducible CYP3A gene. Pharmacogenetics. 11:111–121. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dhaini HR, Thomas DG, Giordano TJ, et al:
Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in
osteosarcoma. J Clin Oncol. 21:2481–2485. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Borst L, Wallerek S, Dalhoff K, Rasmussen
KK, Wesenberg F, Wehner PS and Schmiegelow K: The impact of
CYP3A5*3 on risk and prognosis in childhood acute
lymphoblastic leukemia. Eur J Haematol. 86:477–483. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gréen H, Khan MS, Jakobsen-Falk I,
Avall-Lundqvist E and Peterson C: Impact of CYP3A5*3 and
CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in
patients with ovarian cancer. J Pharm Sci. Jun 23–2011.(Epub ahead
of print).
|
|
36
|
Maquat LE: When cells stop making sense:
effects of nonsense codons on RNA metabolism in vertebrate cells.
RNA. 1:453–465. 1995.PubMed/NCBI
|
|
37
|
Kuehl P, Zhang J, Lin Y, et al: Sequence
diversity in CYP3A promoters and characterization of the genetic
basis of polymorphic CYP3A5 expression. Nat Genet. 27:383–391.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lewis AD, Lau DH, Durán GE, Wolf CR and
Sikic BI: Role of cytochrome P-450 from the human CYP3A gene family
in the potentiation of morpholino doxorubicin by human liver
microsomes. Cancer Res. 52:4379–4384. 1992.PubMed/NCBI
|
|
39
|
Xie HG, Wood AJ, Kim RB, Stein CM and
Wilkinson GR: Genetic variability in CYP3A5 and its possible
consequences. Pharmacogenomics. 5:243–272. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wandel C, Witte JS, Hall JM, Stein CM,
Wood AJ and Wilkinson GR: CYP3A activity in African American and
European American men: population differences and functional effect
of the CYP3A4*1B5′-promoter region polymorphism. Clin
Pharmacol Ther. 68:82–91. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Westlind A, Löfberg L, Tindberg N,
Andersson TB and Ingelman-Sundberg M: Interindividual differences
in hepatic expression of CYP3A4: relationship to genetic
polymorphism in the 5′-upstream regulatory region. Biochem Biophys
Res Commun. 259:201–205. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fisher CD, Lickteig AJ, Augustine LM,
Ranger-Moore J, Jackson JP, Ferguson SS and Cherrington NJ: Hepatic
cytochrome P450 enzyme alterations in humans with progressive
stages of nonalcoholic fatty liver disease. Drug Metab Dispos.
37:2087–2094. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rodríguez-Antona C, Donato MT, Pareja E,
Gómez-Lechón MJ and Castell JV: Cytochrome P-450 mRNA expression in
human liver and its relationship with enzyme activity. Arch Biochem
Biophys. 393:308–315. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Garcia-Martín E, Martínez C, Pizarro RM,
Garcia-Gamito FJ, Gullsten H, Raunio H and Agúndez JA: CYP3A4
variant alleles in white individuals with low CYP3A4 enzyme
activity. Clin Pharmacol Ther. 71:196–204. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ball SE, Scatina J, Kao J, et al:
Population distribution and effects on drug metabolism of a genetic
variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther.
66:288–294. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Miyoshi Y, Ando A, Takamura Y, Taguchi T,
Tamaki Y and Noguchi S: Prediction of response to docetaxel by
CYP3A4 mRNA expression in breast cancer tissues. Int J Cancer.
97:129–132. 2002. View Article : Google Scholar : PubMed/NCBI
|
